Real-World Effectiveness, Safety, and Health-Related Quality of Life in Patients Receiving Adjuvant Nivolumab for Melanoma in Belgium and Luxembourg: Results of PRESERV MEL DOI Open Access
Anne Rogiers,

L. Willemot,

Laura McDonald

и другие.

Cancers, Год журнала: 2023, Номер 15(19), С. 4823 - 4823

Опубликована: Сен. 30, 2023

Nivolumab, an anti-programmed cell death 1 immuno-oncology therapy, is approved as adjuvant treatment for patients with completely resected stage III or IV melanoma. PRESERV MEL (Prospective and REtrospective Study of nivolumab thERapy in adjuVant MELanoma) a real-world observational study evaluating the effectiveness safety melanoma clinical practice Belgium Luxembourg.Patients were enrolled prospectively retrospectively during 2-year period (January 2019-January 2021), will be followed 5 years. The results reported here are second interim analysis (cutoff date 31 December 2021). index was first administration nivolumab. Patients received up to 12 months per label. Outcomes included relapse-free survival (RFS), adverse events (AEs)/treatment-related AEs (TRAEs), health-related quality life (HRQoL; assessed using European Organisation Research Treatment Cancer Quality Life Questionnaire C30 (EORTC QLQ-C30), Functional Assessment Therapy-Melanoma (FACT-M), EQ-5D-3L instruments). HRQoL evaluated at group level (mean change scores from baseline based on minimally important differences) individual patient (percentage clinically threshold importance). analyzed descriptively.The 152 (125 prospective, 27 retrospective) 15 hospitals Luxembourg. Minimum potential follow-up time 11.4 months. Median age 60 years (range 29-85), 53% male. At 18 months, RFS rates 74.7% (95% confidence interval (CI): 66.9-80.9) 68.4% CI: 60.0-75.5), respectively. not reached. Grade 3 4 TRAEs 14% patients. led discontinuation 23% Deaths occurred 3% related treatment. completion high (90-94%) 24 (78-81%). In group-level HRQoL, mean changes remained stable did exceed prespecified thresholds differences after treatment, except meaningful improvement FACT-M surgery subscale scores. patient-level EORTC QLQ-C30 subscales, percentages who relevant fatigue cognitive impairment increased (at 9 months) compared baseline. After cessation months), percentage decreased. However, emotional, cognitive, social Most emotional experience disease recurrence (91% 89%, respectively).These confirm Cancer-specific, disease-specific, generic maintained reporting cessation, emphasizing need further investigation tailored supportive care these

Язык: Английский

Cognitive impairment after cancer treatment: mechanisms, clinical characterization, and management DOI

Ben Fleming,

Paul Edison, Laura Kenny

и другие.

BMJ, Год журнала: 2023, Номер unknown, С. e071726 - e071726

Опубликована: Март 15, 2023

Abstract Cognitive impairment is a debilitating side effect experienced by patients with cancer treated systemically administered anticancer therapies. With around 19.3 million new cases of worldwide in 2020 and the five year survival rate growing from 50% 1970 to 67% 2013, an urgent need exists understand enduring effects severe implications for quality life. Whereas cognitive associated chemotherapy recognized breast cancer, researchers have started identify other treatments such as immune, endocrine, targeted therapies only recently. The underlying mechanisms are diverse therapy specific, so further evaluation needed develop effective therapeutic interventions. Drug non-drug management strategies emerging that target mechanistic pathways or deficits themselves, but they be rigorously evaluated. Clinically, consistent use objective diagnostic tools necessary accurate diagnosis clinical characterization This should supplemented guidelines could implemented daily practice. review summarizes recent advances mechanisms, characterization, novel treatment non-central nervous system cancers.

Язык: Английский

Процитировано

45
Immunotherapy-related cognitive impairment after CAR T cell therapy in mice DOI Creative Commons
Anna C. Geraghty, Lehi Acosta-Alvarez, Maria Caterina Rotiroti

и другие.

Cell, Год журнала: 2025, Номер unknown

Опубликована: Май 1, 2025

Язык: Английский

Процитировано

3
Concentrations of S100B and neurofilament light chain in blood as biomarkers for checkpoint inhibitor–induced CNS inflammation DOI Creative Commons
Sara Bjursten, Zhiyuan Zhao,

Hifaa Al Remawi

и другие.

EBioMedicine, Год журнала: 2024, Номер 100, С. 104955 - 104955

Опубликована: Янв. 3, 2024

Cancer treatment with immune checkpoint inhibition (ICI) can cause immune-related adverse events in the central nervous system (CNS irAE). There are no blood biomarkers to detect CNS irAE. We investigated if concentrations of S100-calcium-binding protein B (S100B) and neurofilament light chain (NfL) be used as for irAE assessed incidence a cohort ICI-treated patients.

Язык: Английский

Процитировано

16
Recent advances in 3D bioprinting for cancer research: From precision models to personalized therapies DOI

Ruchika,

Neha Bhardwaj, Sudesh Kumar Yadav

и другие.

Drug Discovery Today, Год журнала: 2024, Номер 29(4), С. 103924 - 103924

Опубликована: Фев. 22, 2024

Язык: Английский

Процитировано

11
Targeted delivery and controlled release of polymeric nanomedicines for tumor therapy DOI Creative Commons
Na Shen, Weidong Zhao,

Hongyu Chu

и другие.

Fundamental Research, Год журнала: 2025, Номер unknown

Опубликована: Янв. 1, 2025

Язык: Английский

Процитировано

2
CJ2: A Novel Potent Platinum(IV) Prodrug Enhances Chemo-Immunotherapy by Facilitating PD-L1 Degradation in the Cytoplasm and Cytomembrane DOI

Renming Fan,

Aohua Deng,

Bing Qi

и другие.

Journal of Medicinal Chemistry, Год журнала: 2023, Номер 66(1), С. 875 - 889

Опубликована: Янв. 3, 2023

Platinum drugs as primary chemotherapy have been applied to various cancer patients. However, their therapeutic applicability is limited due the adverse effects and immunosuppression. To minimize side boost immune response, we designed synthesized platinum(IV) prodrugs that introduced BRD4 inhibitor JQ-1. Among them, CJ2 had most potent activity less toxicity. With introduction of ligand JQ-1, CJ2-reduced PD-L1 protein was found in cytoplasm cytomembrane for first time. By interfering with synthesis, could arouse system promote CD8+ T cell infiltration. Meanwhile, accelerate degradation block DNA damage repair. In vivo, markedly suppressed tumor growth by reversing immunosuppression microenvironment enhancing damage. These findings provide an effective approach improve selectivity platinum elevated response.

Язык: Английский

Процитировано

22
Cognitive impairment following breast cancer treatments: an umbrella review DOI Creative Commons
Giulia Oliva, Andreina Giustiniani, Laura Danesin

и другие.

The Oncologist, Год журнала: 2024, Номер 29(7), С. e848 - e863

Опубликована: Май 9, 2024

Cancer-related cognitive impairment (CRCI) refers to a decline associated with cancer or its treatments. While research into CRCI is expanding, evidence remains scattered due differences in study designs, methodologies, and definitions. The present umbrella review aims provide comprehensive overview of the current regarding impact different breast therapies on functioning, particular focus interplay among objective deficits (ie, measured standardized tests), subjective concerns, self-reported), other mediating psycho-physical factors.

Язык: Английский

Процитировано

9
Elevated C-Reactive Protein and Subsequent Patient-Reported Cognitive Problems in Older Breast Cancer Survivors: The Thinking and Living With Cancer Study DOI
Judith Carroll, Zev M. Nakamura, Brent J. Small

и другие.

Journal of Clinical Oncology, Год журнала: 2022, Номер 41(2), С. 295 - 306

Опубликована: Сен. 30, 2022

To examine longitudinal relationships between levels of C-reactive protein (CRP) and cognition in older breast cancer survivors noncancer controls.

Язык: Английский

Процитировано

26
Fully implantable and battery-free wireless optoelectronic system for modulable cancer therapy and real-time monitoring DOI Creative Commons

Kiho Kim,

In Sik Min, Tae Hee Kim

и другие.

npj Flexible Electronics, Год журнала: 2023, Номер 7(1)

Опубликована: Авг. 28, 2023

Abstract Photodynamic therapy (PDT) is attracting attention as a next-generation cancer treatment that can selectively destroy malignant tissues, exhibit fewer side effects, and lack pain during treatments. Implantable PDT systems have recently been developed to resolve the issues of bulky expensive conventional implement continuous repetitive treatment. Existing implantable systems, however, are not able perform multiple functions simultaneously, such modulating light intensity, measuring, transmitting tumor-related data, resulting in complexity Here, we introduce flexible fully wireless optoelectronic system capable effective by fusing hyperthermia enabling tumor size monitoring real-time. This exploits micro inorganic light-emitting diodes (μ-LED) emit with wavelength 624 nm, designed affect surrounding normal tissues utilizing programmable intensity μ-LED precisely Si phototransistor long-term implantation (2–3 weeks). The superiority simultaneous capabilities our operated power data transmissions cell phone was confirmed through vitro experiments, ray-tracing simulation results, xenograft mouse model vivo. all-in-one single for offers opportunities only enable tumors located deep tissue but also precise

Язык: Английский

Процитировано

14
Neurological Complications of Conventional and Novel Anticancer Treatments DOI Open Access
Paola Alberti, Alessandro Salvalaggio, Andreas A. Argyriou

и другие.

Cancers, Год журнала: 2022, Номер 14(24), С. 6088 - 6088

Опубликована: Дек. 10, 2022

Various neurological complications, affecting both the central and peripheral nervous system, can frequently be experienced by cancer survivors after exposure to conventional chemotherapy, but also modern immunotherapy. In this review, we provide an overview of most well-known adverse events related with a focus on chemotherapy induced neurotoxicity, address some emerging novel clinical entities treatment, including chemotherapy-related cognitive impairment immune-mediated events. Unfortunately, efficacious curative or preventive treatment for all these complications is still lacking. We description possible mechanisms involved drive future drug discovery in field, symptomatic neuroprotection.

Язык: Английский

Процитировано

22